Growth / Performance
CJC-1295 (No DAC)
C₁₅₂H₂₅₂N₄₄O₄₂
Key Research Findings
- Produces pulsatile GH release consistent with physiological patterns, preserving feedback regulation.
- Often combined with GHRP peptides (e.g., Ipamorelin) for synergistic GH secretion.
- Amino acid substitutions at positions 2, 8, 15, and 27 significantly improve plasma stability.
- Absence of DAC moiety results in shorter half-life (~30 min) versus the DAC version (~6–8 days).
Overview
CJC-1295 without DAC (also known as Modified GRF 1–29 or Mod GRF 1–29) is a 29-amino acid analogue of growth hormone-releasing hormone (GHRH). It contains four amino acid substitutions that increase its stability and receptor affinity compared to native GHRH, while the absence of the Drug Affinity Complex (DAC) preserves a shorter, more physiological half-life.
Mechanism of Action
CJC-1295 (no DAC) binds pituitary GHRH receptors, stimulating somatotroph cells to synthesise and release growth hormone (GH) in a pulsatile, physiological pattern. This preserves the natural GH secretion rhythm, avoiding the receptor desensitisation associated with continuous GH exposure.
Research Effects
GH Secretion
Extensive ResearchConsistently shown to stimulate pulsatile GH release from pituitary somatotrophs in animal and human studies.
IGF-1 Elevation
Extensive ResearchSecondary to GH release; downstream IGF-1 increase drives anabolic and recovery effects in research models.
Body Composition
Moderate ResearchAnimal studies and human research indicate improved lean body mass and reduced adiposity following GH restoration.
Recovery
Moderate ResearchEnhanced GH pulses associated with faster recovery from tissue stress in exercise and injury research models.
Research Purposes Only — All information on this page is provided for scientific research purposes only. This product is not intended for human consumption, diagnosis, treatment, or prevention of any disease.
Quick Facts
Research Status Key
Related Peptides
Growth / Performance
Ipamorelin
Ipamorelin is a selective growth hormone secretagogue and ghrelin receptor agonist (GHSR-1a) consisting of 5 amino acids. It is studied for its highly selective GH-releasing properties, producing significant GH pulses without the concomitant cortisol, prolactin, or ACTH release seen with first-generation GHRPs.
Learn More →
Growth / Performance
GHRP-6
GHRP-6 is a first-generation synthetic hexapeptide growth hormone releasing peptide that acts as a potent agonist of the ghrelin receptor (GHSR-1a). It was among the first GHRP compounds studied and remains a reference compound for GH secretagogue research.
Learn More →
Growth / Performance
Tesamorelin
Tesamorelin is a synthetic analogue of GHRH consisting of the full 44-amino acid sequence of native GHRH modified with a trans-3-hexenoic acid group at the N-terminus, enhancing stability. It is the only FDA-approved GHRH analogue, licensed for HIV-associated lipodystrophy treatment under the name Egrifta.
Learn More →